nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—S100B—urinary bladder cancer	0.767	1	CbGaD
Olopatadine—S100A2—prostate gland—urinary bladder cancer	0.00558	0.0708	CbGeAlD
Olopatadine—S100A1—prostate gland—urinary bladder cancer	0.00514	0.0652	CbGeAlD
Olopatadine—S100A2—seminal vesicle—urinary bladder cancer	0.00472	0.0599	CbGeAlD
Olopatadine—S100A13—prostate gland—urinary bladder cancer	0.00456	0.0579	CbGeAlD
Olopatadine—S100A12—prostate gland—urinary bladder cancer	0.0045	0.0571	CbGeAlD
Olopatadine—S100A2—epithelium—urinary bladder cancer	0.0041	0.052	CbGeAlD
Olopatadine—S100A2—renal system—urinary bladder cancer	0.0038	0.0483	CbGeAlD
Olopatadine—S100A2—urethra—urinary bladder cancer	0.00374	0.0474	CbGeAlD
Olopatadine—S100A1—renal system—urinary bladder cancer	0.0035	0.0445	CbGeAlD
Olopatadine—S100A13—epithelium—urinary bladder cancer	0.00335	0.0425	CbGeAlD
Olopatadine—S100A12—epithelium—urinary bladder cancer	0.00331	0.0419	CbGeAlD
Olopatadine—S100A13—smooth muscle tissue—urinary bladder cancer	0.00323	0.041	CbGeAlD
Olopatadine—S100A13—renal system—urinary bladder cancer	0.00311	0.0394	CbGeAlD
Olopatadine—S100A2—female reproductive system—urinary bladder cancer	0.00305	0.0387	CbGeAlD
Olopatadine—S100A1—female reproductive system—urinary bladder cancer	0.00281	0.0356	CbGeAlD
Olopatadine—S100A2—vagina—urinary bladder cancer	0.00276	0.035	CbGeAlD
Olopatadine—S100A13—female reproductive system—urinary bladder cancer	0.00249	0.0316	CbGeAlD
Olopatadine—S100A12—vagina—urinary bladder cancer	0.00222	0.0282	CbGeAlD
Olopatadine—CYP3A4—urine—urinary bladder cancer	0.00196	0.0249	CbGeAlD
Olopatadine—S100A1—lymph node—urinary bladder cancer	0.00164	0.0208	CbGeAlD
Olopatadine—S100A13—lymph node—urinary bladder cancer	0.00146	0.0185	CbGeAlD
Olopatadine—S100A12—lymph node—urinary bladder cancer	0.00144	0.0182	CbGeAlD
Olopatadine—S100B—lymph node—urinary bladder cancer	0.00142	0.018	CbGeAlD
Olopatadine—S100A12—ZBP1(DAI) mediated induction of type I IFNs—S100B—urinary bladder cancer	0.00138	0.0184	CbGpPWpGaD
Olopatadine—S100A12—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—S100B—urinary bladder cancer	0.00138	0.0184	CbGpPWpGaD
Olopatadine—S100B—Nuclear signaling by ERBB4—RBX1—urinary bladder cancer	0.0013	0.0174	CbGpPWpGaD
Olopatadine—S100A2—p73 transcription factor network—FAS—urinary bladder cancer	0.00129	0.0172	CbGpPWpGaD
Olopatadine—S100A2—Validated transcriptional targets of TAp63 isoforms—CDKN2A—urinary bladder cancer	0.00118	0.0157	CbGpPWpGaD
Olopatadine—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00111	0.0148	CbGpPWpGaD
Olopatadine—S100A2—p73 transcription factor network—RB1—urinary bladder cancer	0.000987	0.0132	CbGpPWpGaD
Olopatadine—S100A2—Validated transcriptional targets of TAp63 isoforms—CDKN1A—urinary bladder cancer	0.000962	0.0128	CbGpPWpGaD
Olopatadine—S100A2—Validated transcriptional targets of TAp63 isoforms—EP300—urinary bladder cancer	0.000915	0.0122	CbGpPWpGaD
Olopatadine—HRH1—prostate gland—urinary bladder cancer	0.000911	0.0116	CbGeAlD
Olopatadine—S100A2—Direct p53 effectors—GPX1—urinary bladder cancer	0.000872	0.0116	CbGpPWpGaD
Olopatadine—S100B—Nuclear signaling by ERBB4—NCOR1—urinary bladder cancer	0.000849	0.0113	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—FAS—urinary bladder cancer	0.000816	0.0109	CbGpPWpGaD
Olopatadine—S100A12—MyD88-independent cascade—BIRC3—urinary bladder cancer	0.000797	0.0106	CbGpPWpGaD
Olopatadine—S100B—MyD88-independent cascade—BIRC3—urinary bladder cancer	0.000753	0.01	CbGpPWpGaD
Olopatadine—S100A12—Activated TLR4 signalling—BIRC3—urinary bladder cancer	0.000717	0.00956	CbGpPWpGaD
Olopatadine—S100A2—p73 transcription factor network—CDKN1A—urinary bladder cancer	0.000709	0.00946	CbGpPWpGaD
Olopatadine—S100B—Activated TLR4 signalling—BIRC3—urinary bladder cancer	0.000678	0.00904	CbGpPWpGaD
Olopatadine—S100A2—p73 transcription factor network—EP300—urinary bladder cancer	0.000675	0.009	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—BIRC3—urinary bladder cancer	0.000674	0.00899	CbGpPWpGaD
Olopatadine—HRH1—epithelium—urinary bladder cancer	0.000669	0.00849	CbGeAlD
Olopatadine—S100B—Nuclear signaling by ERBB4—ESR1—urinary bladder cancer	0.000667	0.0089	CbGpPWpGaD
Olopatadine—S100A12—Cytosolic sensors of pathogen-associated DNA—S100B—urinary bladder cancer	0.000656	0.00875	CbGpPWpGaD
Olopatadine—HRH1—smooth muscle tissue—urinary bladder cancer	0.000645	0.00818	CbGeAlD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—BIRC3—urinary bladder cancer	0.000637	0.0085	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—CREBBP—urinary bladder cancer	0.000627	0.00836	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—RB1—urinary bladder cancer	0.000625	0.00833	CbGpPWpGaD
Olopatadine—HRH1—urethra—urinary bladder cancer	0.00061	0.00774	CbGeAlD
Olopatadine—S100A12—Toll-Like Receptors Cascades—BIRC3—urinary bladder cancer	0.0006	0.00801	CbGpPWpGaD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IFNA2—urinary bladder cancer	0.000595	0.00793	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—S100B—urinary bladder cancer	0.000592	0.0079	CbGpPWpGaD
Olopatadine—S100A2—p73 transcription factor network—MYC—urinary bladder cancer	0.000588	0.00784	CbGpPWpGaD
Olopatadine—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.000578	0.00771	CbGpPWpGaD
Olopatadine—S100B—Toll-Like Receptors Cascades—BIRC3—urinary bladder cancer	0.000568	0.00757	CbGpPWpGaD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IFNA2—urinary bladder cancer	0.000562	0.0075	CbGpPWpGaD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—S100B—urinary bladder cancer	0.000562	0.0075	CbGpPWpGaD
Olopatadine—S100A12—MyD88 cascade initiated on plasma membrane—S100B—urinary bladder cancer	0.000536	0.00714	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—S100B—urinary bladder cancer	0.000531	0.00708	CbGpPWpGaD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—S100B—urinary bladder cancer	0.000521	0.00695	CbGpPWpGaD
Olopatadine—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.000511	0.00682	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—S100B—urinary bladder cancer	0.000503	0.00671	CbGpPWpGaD
Olopatadine—HRH1—female reproductive system—urinary bladder cancer	0.000497	0.00631	CbGeAlD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—S100B—urinary bladder cancer	0.000494	0.00659	CbGpPWpGaD
Olopatadine—CYP3A4—renal system—urinary bladder cancer	0.00048	0.00609	CbGeAlD
Olopatadine—S100A12—MyD88-independent cascade—S100B—urinary bladder cancer	0.000474	0.00632	CbGpPWpGaD
Olopatadine—HRH1—vagina—urinary bladder cancer	0.00045	0.0057	CbGeAlD
Olopatadine—S100A2—Direct p53 effectors—CDKN1A—urinary bladder cancer	0.000449	0.00598	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—PTEN—urinary bladder cancer	0.000448	0.00597	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—RBX1—urinary bladder cancer	0.000439	0.00586	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—EP300—urinary bladder cancer	0.000427	0.00569	CbGpPWpGaD
Olopatadine—S100A12—Activated TLR4 signalling—S100B—urinary bladder cancer	0.000427	0.00569	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000415	0.00553	CbGpPWpGaD
Olopatadine—S100A12—Cytosolic sensors of pathogen-associated DNA—CREBBP—urinary bladder cancer	0.000406	0.00541	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—S100B—urinary bladder cancer	0.000401	0.00535	CbGpPWpGaD
Olopatadine—CYP3A4—female reproductive system—urinary bladder cancer	0.000384	0.00488	CbGeAlD
Olopatadine—S100B—Cytosolic sensors of pathogen-associated DNA—CREBBP—urinary bladder cancer	0.000384	0.00512	CbGpPWpGaD
Olopatadine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000364	0.00486	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—EGFR—urinary bladder cancer	0.000364	0.00485	CbGpPWpGaD
Olopatadine—S100A12—Toll-Like Receptors Cascades—S100B—urinary bladder cancer	0.000357	0.00477	CbGpPWpGaD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—CREBBP—urinary bladder cancer	0.000348	0.00464	CbGpPWpGaD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—CREBBP—urinary bladder cancer	0.000329	0.00439	CbGpPWpGaD
Olopatadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000313	0.00417	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—TP53—urinary bladder cancer	0.000306	0.00408	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PRSS3—urinary bladder cancer	0.000291	0.00389	CbGpPWpGaD
Olopatadine—HRH1—lymph node—urinary bladder cancer	0.000291	0.00369	CbGeAlD
Olopatadine—S100B—Signaling by ERBB4—NCOR1—urinary bladder cancer	0.000286	0.00382	CbGpPWpGaD
Olopatadine—S100A12—Cytosolic sensors of pathogen-associated DNA—EP300—urinary bladder cancer	0.000276	0.00369	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PRSS3—urinary bladder cancer	0.000276	0.00368	CbGpPWpGaD
Olopatadine—S100B—Cytosolic sensors of pathogen-associated DNA—EP300—urinary bladder cancer	0.000261	0.00349	CbGpPWpGaD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—EP300—urinary bladder cancer	0.000237	0.00316	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—FGFR3—urinary bladder cancer	0.000231	0.00309	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—ESR1—urinary bladder cancer	0.000225	0.003	CbGpPWpGaD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—EP300—urinary bladder cancer	0.000224	0.00299	CbGpPWpGaD
Olopatadine—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000223	0.00298	CbGpPWpGaD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000199	0.00265	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000196	0.00261	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—BIRC3—urinary bladder cancer	0.000194	0.00259	CbGpPWpGaD
Olopatadine—Malaise—Cisplatin—urinary bladder cancer	0.00019	0.00241	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000189	0.0024	CcSEcCtD
Olopatadine—Fatigue—Thiotepa—urinary bladder cancer	0.000189	0.00239	CcSEcCtD
Olopatadine—Dysgeusia—Etoposide—urinary bladder cancer	0.000189	0.00239	CcSEcCtD
Olopatadine—Pain—Thiotepa—urinary bladder cancer	0.000187	0.00237	CcSEcCtD
Olopatadine—Discomfort—Fluorouracil—urinary bladder cancer	0.000187	0.00237	CcSEcCtD
Olopatadine—Back pain—Etoposide—urinary bladder cancer	0.000186	0.00236	CcSEcCtD
Olopatadine—Muscle spasms—Etoposide—urinary bladder cancer	0.000185	0.00235	CcSEcCtD
Olopatadine—Oedema—Gemcitabine—urinary bladder cancer	0.000184	0.00234	CcSEcCtD
Olopatadine—S100B—Innate Immune System—BIRC3—urinary bladder cancer	0.000184	0.00245	CbGpPWpGaD
Olopatadine—Eye pain—Doxorubicin—urinary bladder cancer	0.000184	0.00233	CcSEcCtD
Olopatadine—Infection—Gemcitabine—urinary bladder cancer	0.000183	0.00232	CcSEcCtD
Olopatadine—Oedema—Fluorouracil—urinary bladder cancer	0.000181	0.0023	CcSEcCtD
Olopatadine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000181	0.00229	CcSEcCtD
Olopatadine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00018	0.00229	CcSEcCtD
Olopatadine—Infection—Fluorouracil—urinary bladder cancer	0.00018	0.00228	CcSEcCtD
Olopatadine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000179	0.00227	CcSEcCtD
Olopatadine—Skin disorder—Gemcitabine—urinary bladder cancer	0.000179	0.00227	CcSEcCtD
Olopatadine—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000179	0.00227	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000178	0.00225	CcSEcCtD
Olopatadine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000178	0.00225	CcSEcCtD
Olopatadine—Discomfort—Cisplatin—urinary bladder cancer	0.000177	0.00224	CcSEcCtD
Olopatadine—Malaise—Etoposide—urinary bladder cancer	0.000174	0.0022	CcSEcCtD
Olopatadine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000173	0.00219	CcSEcCtD
Olopatadine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000173	0.00219	CcSEcCtD
Olopatadine—Oedema—Cisplatin—urinary bladder cancer	0.000172	0.00218	CcSEcCtD
Olopatadine—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000171	0.00228	CbGpPWpGaD
Olopatadine—Infection—Cisplatin—urinary bladder cancer	0.000171	0.00216	CcSEcCtD
Olopatadine—S100A12—Immune System—PRSS3—urinary bladder cancer	0.00017	0.00226	CbGpPWpGaD
Olopatadine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000168	0.00213	CcSEcCtD
Olopatadine—Cough—Etoposide—urinary bladder cancer	0.000168	0.00213	CcSEcCtD
Olopatadine—Skin disorder—Cisplatin—urinary bladder cancer	0.000167	0.00211	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—ERBB2—urinary bladder cancer	0.000165	0.0022	CbGpPWpGaD
Olopatadine—Dry skin—Epirubicin—urinary bladder cancer	0.000164	0.00208	CcSEcCtD
Olopatadine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000164	0.00208	CcSEcCtD
Olopatadine—Somnolence—Gemcitabine—urinary bladder cancer	0.000164	0.00208	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000163	0.00207	CcSEcCtD
Olopatadine—Discomfort—Etoposide—urinary bladder cancer	0.000162	0.00206	CcSEcCtD
Olopatadine—S100A12—Immune System—VHL—urinary bladder cancer	0.000162	0.00216	CbGpPWpGaD
Olopatadine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000161	0.00205	CcSEcCtD
Olopatadine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000161	0.00205	CcSEcCtD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000161	0.00215	CbGpPWpGaD
Olopatadine—Somnolence—Fluorouracil—urinary bladder cancer	0.000161	0.00204	CcSEcCtD
Olopatadine—S100B—Immune System—PRSS3—urinary bladder cancer	0.000161	0.00214	CbGpPWpGaD
Olopatadine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00016	0.00214	CbGpPWpGaD
Olopatadine—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.00016	0.00203	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000159	0.00202	CcSEcCtD
Olopatadine—Fatigue—Gemcitabine—urinary bladder cancer	0.000159	0.00201	CcSEcCtD
Olopatadine—Pain—Gemcitabine—urinary bladder cancer	0.000157	0.002	CcSEcCtD
Olopatadine—Asthenia—Thiotepa—urinary bladder cancer	0.000157	0.00199	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000156	0.00198	CcSEcCtD
Olopatadine—Infection—Etoposide—urinary bladder cancer	0.000156	0.00198	CcSEcCtD
Olopatadine—Influenza—Epirubicin—urinary bladder cancer	0.000155	0.00197	CcSEcCtD
Olopatadine—Pruritus—Thiotepa—urinary bladder cancer	0.000155	0.00196	CcSEcCtD
Olopatadine—Pain—Fluorouracil—urinary bladder cancer	0.000155	0.00196	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000154	0.00195	CcSEcCtD
Olopatadine—S100B—Immune System—VHL—urinary bladder cancer	0.000153	0.00204	CbGpPWpGaD
Olopatadine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000153	0.00194	CcSEcCtD
Olopatadine—Skin disorder—Etoposide—urinary bladder cancer	0.000153	0.00194	CcSEcCtD
Olopatadine—S100A12—Immune System—MT2A—urinary bladder cancer	0.000152	0.00203	CbGpPWpGaD
Olopatadine—Dry skin—Doxorubicin—urinary bladder cancer	0.000152	0.00193	CcSEcCtD
Olopatadine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000152	0.00192	CcSEcCtD
Olopatadine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00015	0.0019	CcSEcCtD
Olopatadine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000149	0.00189	CcSEcCtD
Olopatadine—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000148	0.00188	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000148	0.00188	CcSEcCtD
Olopatadine—Infestation—Methotrexate—urinary bladder cancer	0.000148	0.00187	CcSEcCtD
Olopatadine—Infestation NOS—Methotrexate—urinary bladder cancer	0.000148	0.00187	CcSEcCtD
Olopatadine—Depression—Methotrexate—urinary bladder cancer	0.000147	0.00187	CcSEcCtD
Olopatadine—Pain—Cisplatin—urinary bladder cancer	0.000147	0.00186	CcSEcCtD
Olopatadine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000146	0.00185	CcSEcCtD
Olopatadine—Dizziness—Thiotepa—urinary bladder cancer	0.000145	0.00184	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000144	0.00183	CcSEcCtD
Olopatadine—S100B—Immune System—MT2A—urinary bladder cancer	0.000144	0.00192	CbGpPWpGaD
Olopatadine—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000144	0.00182	CcSEcCtD
Olopatadine—Influenza—Doxorubicin—urinary bladder cancer	0.000143	0.00182	CcSEcCtD
Olopatadine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000143	0.00182	CcSEcCtD
Olopatadine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000141	0.00179	CcSEcCtD
Olopatadine—Weight increased—Epirubicin—urinary bladder cancer	0.000141	0.00179	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—CDKN1A—urinary bladder cancer	0.000141	0.00188	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—PTEN—urinary bladder cancer	0.000141	0.00188	CbGpPWpGaD
Olopatadine—Dyspnoea—Etoposide—urinary bladder cancer	0.00014	0.00178	CcSEcCtD
Olopatadine—Somnolence—Etoposide—urinary bladder cancer	0.00014	0.00177	CcSEcCtD
Olopatadine—Epistaxis—Methotrexate—urinary bladder cancer	0.000139	0.00177	CcSEcCtD
Olopatadine—Vomiting—Thiotepa—urinary bladder cancer	0.000139	0.00176	CcSEcCtD
Olopatadine—Infestation—Epirubicin—urinary bladder cancer	0.000138	0.00175	CcSEcCtD
Olopatadine—Infestation NOS—Epirubicin—urinary bladder cancer	0.000138	0.00175	CcSEcCtD
Olopatadine—Rash—Thiotepa—urinary bladder cancer	0.000138	0.00175	CcSEcCtD
Olopatadine—Dermatitis—Thiotepa—urinary bladder cancer	0.000138	0.00175	CcSEcCtD
Olopatadine—Headache—Thiotepa—urinary bladder cancer	0.000137	0.00174	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000136	0.00172	CcSEcCtD
Olopatadine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000136	0.00172	CcSEcCtD
Olopatadine—Fatigue—Etoposide—urinary bladder cancer	0.000136	0.00172	CcSEcCtD
Olopatadine—Pain—Etoposide—urinary bladder cancer	0.000134	0.00171	CcSEcCtD
Olopatadine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000134	0.0017	CcSEcCtD
Olopatadine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000134	0.0017	CcSEcCtD
Olopatadine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000133	0.00169	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000133	0.00169	CcSEcCtD
Olopatadine—Asthenia—Gemcitabine—urinary bladder cancer	0.000132	0.00168	CcSEcCtD
Olopatadine—Pharyngitis—Methotrexate—urinary bladder cancer	0.000132	0.00167	CcSEcCtD
Olopatadine—Weight increased—Doxorubicin—urinary bladder cancer	0.000131	0.00166	CcSEcCtD
Olopatadine—Epistaxis—Epirubicin—urinary bladder cancer	0.00013	0.00165	CcSEcCtD
Olopatadine—Pruritus—Gemcitabine—urinary bladder cancer	0.00013	0.00165	CcSEcCtD
Olopatadine—Nausea—Thiotepa—urinary bladder cancer	0.00013	0.00165	CcSEcCtD
Olopatadine—Sinusitis—Epirubicin—urinary bladder cancer	0.00013	0.00164	CcSEcCtD
Olopatadine—Feeling abnormal—Etoposide—urinary bladder cancer	0.00013	0.00164	CcSEcCtD
Olopatadine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000129	0.00163	CcSEcCtD
Olopatadine—Pruritus—Fluorouracil—urinary bladder cancer	0.000128	0.00162	CcSEcCtD
Olopatadine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000128	0.00162	CcSEcCtD
Olopatadine—Infestation—Doxorubicin—urinary bladder cancer	0.000128	0.00162	CcSEcCtD
Olopatadine—Visual impairment—Methotrexate—urinary bladder cancer	0.000128	0.00162	CcSEcCtD
Olopatadine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000126	0.0016	CcSEcCtD
Olopatadine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000126	0.0016	CcSEcCtD
Olopatadine—Rhinitis—Epirubicin—urinary bladder cancer	0.000124	0.00158	CcSEcCtD
Olopatadine—Body temperature increased—Etoposide—urinary bladder cancer	0.000124	0.00158	CcSEcCtD
Olopatadine—Abdominal pain—Etoposide—urinary bladder cancer	0.000124	0.00158	CcSEcCtD
Olopatadine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000124	0.00158	CcSEcCtD
Olopatadine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000124	0.00158	CcSEcCtD
Olopatadine—Eye disorder—Methotrexate—urinary bladder cancer	0.000124	0.00157	CcSEcCtD
Olopatadine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000124	0.00157	CcSEcCtD
Olopatadine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000123	0.00157	CcSEcCtD
Olopatadine—Asthenia—Cisplatin—urinary bladder cancer	0.000123	0.00156	CcSEcCtD
Olopatadine—Pharyngitis—Epirubicin—urinary bladder cancer	0.000123	0.00156	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—IFNA2—urinary bladder cancer	0.000122	0.00163	CbGpPWpGaD
Olopatadine—Epistaxis—Doxorubicin—urinary bladder cancer	0.000121	0.00153	CcSEcCtD
Olopatadine—Sinusitis—Doxorubicin—urinary bladder cancer	0.00012	0.00152	CcSEcCtD
Olopatadine—Immune system disorder—Methotrexate—urinary bladder cancer	0.00012	0.00152	CcSEcCtD
Olopatadine—Dizziness—Fluorouracil—urinary bladder cancer	0.00012	0.00152	CcSEcCtD
Olopatadine—Visual impairment—Epirubicin—urinary bladder cancer	0.00012	0.00152	CcSEcCtD
Olopatadine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000119	0.00152	CcSEcCtD
Olopatadine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000117	0.00149	CcSEcCtD
Olopatadine—Vomiting—Gemcitabine—urinary bladder cancer	0.000117	0.00148	CcSEcCtD
Olopatadine—Rash—Gemcitabine—urinary bladder cancer	0.000116	0.00147	CcSEcCtD
Olopatadine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000116	0.00147	CcSEcCtD
Olopatadine—Eye disorder—Epirubicin—urinary bladder cancer	0.000116	0.00147	CcSEcCtD
Olopatadine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000116	0.00147	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—S100B—urinary bladder cancer	0.000116	0.00154	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IFNA2—urinary bladder cancer	0.000116	0.00154	CbGpPWpGaD
Olopatadine—Erythema—Methotrexate—urinary bladder cancer	0.000115	0.00146	CcSEcCtD
Olopatadine—Headache—Gemcitabine—urinary bladder cancer	0.000115	0.00146	CcSEcCtD
Olopatadine—Vomiting—Fluorouracil—urinary bladder cancer	0.000115	0.00146	CcSEcCtD
Olopatadine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000115	0.00146	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—EGFR—urinary bladder cancer	0.000114	0.00152	CbGpPWpGaD
Olopatadine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000114	0.00145	CcSEcCtD
Olopatadine—Rash—Fluorouracil—urinary bladder cancer	0.000114	0.00145	CcSEcCtD
Olopatadine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000114	0.00145	CcSEcCtD
Olopatadine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000114	0.00144	CcSEcCtD
Olopatadine—Headache—Fluorouracil—urinary bladder cancer	0.000113	0.00144	CcSEcCtD
Olopatadine—S100A12—Immune System—BIRC3—urinary bladder cancer	0.000113	0.00151	CbGpPWpGaD
Olopatadine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000113	0.00143	CcSEcCtD
Olopatadine—Asthenia—Etoposide—urinary bladder cancer	0.000113	0.00143	CcSEcCtD
Olopatadine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000112	0.00142	CcSEcCtD
Olopatadine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000112	0.00142	CcSEcCtD
Olopatadine—Back pain—Methotrexate—urinary bladder cancer	0.000112	0.00142	CcSEcCtD
Olopatadine—Pruritus—Etoposide—urinary bladder cancer	0.000111	0.00141	CcSEcCtD
Olopatadine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000111	0.0014	CcSEcCtD
Olopatadine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.00011	0.00146	CbGpPWpGaD
Olopatadine—Nausea—Gemcitabine—urinary bladder cancer	0.000109	0.00139	CcSEcCtD
Olopatadine—Vomiting—Cisplatin—urinary bladder cancer	0.000109	0.00138	CcSEcCtD
Olopatadine—Vision blurred—Methotrexate—urinary bladder cancer	0.000109	0.00138	CcSEcCtD
Olopatadine—Rash—Cisplatin—urinary bladder cancer	0.000108	0.00137	CcSEcCtD
Olopatadine—Dermatitis—Cisplatin—urinary bladder cancer	0.000108	0.00137	CcSEcCtD
Olopatadine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000108	0.00144	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—KRAS—urinary bladder cancer	0.000108	0.00144	CbGpPWpGaD
Olopatadine—Erythema—Epirubicin—urinary bladder cancer	0.000108	0.00137	CcSEcCtD
Olopatadine—Diarrhoea—Etoposide—urinary bladder cancer	0.000108	0.00136	CcSEcCtD
Olopatadine—Nausea—Fluorouracil—urinary bladder cancer	0.000108	0.00136	CcSEcCtD
Olopatadine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000107	0.00136	CcSEcCtD
Olopatadine—S100B—Immune System—BIRC3—urinary bladder cancer	0.000107	0.00143	CbGpPWpGaD
Olopatadine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000107	0.00136	CcSEcCtD
Olopatadine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000106	0.00134	CcSEcCtD
Olopatadine—Back pain—Epirubicin—urinary bladder cancer	0.000104	0.00132	CcSEcCtD
Olopatadine—Malaise—Methotrexate—urinary bladder cancer	0.000104	0.00132	CcSEcCtD
Olopatadine—Dizziness—Etoposide—urinary bladder cancer	0.000104	0.00132	CcSEcCtD
Olopatadine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000104	0.00139	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000104	0.00139	CbGpPWpGaD
Olopatadine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000104	0.00132	CcSEcCtD
Olopatadine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000104	0.00131	CcSEcCtD
Olopatadine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000103	0.00131	CcSEcCtD
Olopatadine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000102	0.00137	CbGpPWpGaD
Olopatadine—Nausea—Cisplatin—urinary bladder cancer	0.000102	0.00129	CcSEcCtD
Olopatadine—Vision blurred—Epirubicin—urinary bladder cancer	0.000102	0.00129	CcSEcCtD
Olopatadine—Cough—Methotrexate—urinary bladder cancer	0.000101	0.00128	CcSEcCtD
Olopatadine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.0001	0.00127	CcSEcCtD
Olopatadine—Vomiting—Etoposide—urinary bladder cancer	0.0001	0.00127	CcSEcCtD
Olopatadine—Erythema—Doxorubicin—urinary bladder cancer	9.99e-05	0.00127	CcSEcCtD
Olopatadine—Rash—Etoposide—urinary bladder cancer	9.91e-05	0.00126	CcSEcCtD
Olopatadine—Dermatitis—Etoposide—urinary bladder cancer	9.9e-05	0.00126	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—HDAC4—urinary bladder cancer	9.9e-05	0.00132	CbGpPWpGaD
Olopatadine—Headache—Etoposide—urinary bladder cancer	9.85e-05	0.00125	CcSEcCtD
Olopatadine—Dysgeusia—Doxorubicin—urinary bladder cancer	9.79e-05	0.00124	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	9.76e-05	0.00124	CcSEcCtD
Olopatadine—Malaise—Epirubicin—urinary bladder cancer	9.74e-05	0.00124	CcSEcCtD
Olopatadine—Discomfort—Methotrexate—urinary bladder cancer	9.71e-05	0.00123	CcSEcCtD
Olopatadine—Back pain—Doxorubicin—urinary bladder cancer	9.67e-05	0.00123	CcSEcCtD
Olopatadine—Muscle spasms—Doxorubicin—urinary bladder cancer	9.61e-05	0.00122	CcSEcCtD
Olopatadine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	9.5e-05	0.00127	CbGpPWpGaD
Olopatadine—Cough—Epirubicin—urinary bladder cancer	9.42e-05	0.0012	CcSEcCtD
Olopatadine—Vision blurred—Doxorubicin—urinary bladder cancer	9.42e-05	0.00119	CcSEcCtD
Olopatadine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	9.37e-05	0.00125	CbGpPWpGaD
Olopatadine—Infection—Methotrexate—urinary bladder cancer	9.36e-05	0.00119	CcSEcCtD
Olopatadine—Nausea—Etoposide—urinary bladder cancer	9.34e-05	0.00118	CcSEcCtD
Olopatadine—S100A12—Immune System—RBX1—urinary bladder cancer	9.3e-05	0.00124	CbGpPWpGaD
Olopatadine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	9.27e-05	0.00118	CcSEcCtD
Olopatadine—Nervous system disorder—Methotrexate—urinary bladder cancer	9.24e-05	0.00117	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—HRAS—urinary bladder cancer	9.18e-05	0.00122	CbGpPWpGaD
Olopatadine—Skin disorder—Methotrexate—urinary bladder cancer	9.15e-05	0.00116	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	9.13e-05	0.00116	CcSEcCtD
Olopatadine—Discomfort—Epirubicin—urinary bladder cancer	9.08e-05	0.00115	CcSEcCtD
Olopatadine—Malaise—Doxorubicin—urinary bladder cancer	9.01e-05	0.00114	CcSEcCtD
Olopatadine—Dry mouth—Epirubicin—urinary bladder cancer	8.99e-05	0.00114	CcSEcCtD
Olopatadine—Oedema—Epirubicin—urinary bladder cancer	8.81e-05	0.00112	CcSEcCtD
Olopatadine—S100B—Immune System—RBX1—urinary bladder cancer	8.8e-05	0.00117	CbGpPWpGaD
Olopatadine—Infection—Epirubicin—urinary bladder cancer	8.76e-05	0.00111	CcSEcCtD
Olopatadine—Cough—Doxorubicin—urinary bladder cancer	8.72e-05	0.00111	CcSEcCtD
Olopatadine—Nervous system disorder—Epirubicin—urinary bladder cancer	8.64e-05	0.0011	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—EP300—urinary bladder cancer	8.57e-05	0.00114	CbGpPWpGaD
Olopatadine—Skin disorder—Epirubicin—urinary bladder cancer	8.56e-05	0.00109	CcSEcCtD
Olopatadine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	8.56e-05	0.00114	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	8.45e-05	0.00107	CcSEcCtD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	8.44e-05	0.00113	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—FGFR3—urinary bladder cancer	8.42e-05	0.00112	CbGpPWpGaD
Olopatadine—Discomfort—Doxorubicin—urinary bladder cancer	8.4e-05	0.00107	CcSEcCtD
Olopatadine—Dyspnoea—Methotrexate—urinary bladder cancer	8.4e-05	0.00106	CcSEcCtD
Olopatadine—Somnolence—Methotrexate—urinary bladder cancer	8.37e-05	0.00106	CcSEcCtD
Olopatadine—Dry mouth—Doxorubicin—urinary bladder cancer	8.32e-05	0.00106	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—GLI1—urinary bladder cancer	8.3e-05	0.00111	CbGpPWpGaD
Olopatadine—Oedema—Doxorubicin—urinary bladder cancer	8.16e-05	0.00103	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.13e-05	0.00103	CcSEcCtD
Olopatadine—Fatigue—Methotrexate—urinary bladder cancer	8.12e-05	0.00103	CcSEcCtD
Olopatadine—Infection—Doxorubicin—urinary bladder cancer	8.1e-05	0.00103	CcSEcCtD
Olopatadine—Pain—Methotrexate—urinary bladder cancer	8.05e-05	0.00102	CcSEcCtD
Olopatadine—Nervous system disorder—Doxorubicin—urinary bladder cancer	8e-05	0.00101	CcSEcCtD
Olopatadine—S100B—Innate Immune System—FGFR3—urinary bladder cancer	7.96e-05	0.00106	CbGpPWpGaD
Olopatadine—Skin disorder—Doxorubicin—urinary bladder cancer	7.92e-05	0.001	CcSEcCtD
Olopatadine—Dyspnoea—Epirubicin—urinary bladder cancer	7.86e-05	0.000997	CcSEcCtD
Olopatadine—Somnolence—Epirubicin—urinary bladder cancer	7.84e-05	0.000994	CcSEcCtD
Olopatadine—Feeling abnormal—Methotrexate—urinary bladder cancer	7.76e-05	0.000984	CcSEcCtD
Olopatadine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.7e-05	0.000977	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.61e-05	0.000965	CcSEcCtD
Olopatadine—Fatigue—Epirubicin—urinary bladder cancer	7.6e-05	0.000964	CcSEcCtD
Olopatadine—Pain—Epirubicin—urinary bladder cancer	7.54e-05	0.000956	CcSEcCtD
Olopatadine—Abdominal pain—Methotrexate—urinary bladder cancer	7.45e-05	0.000944	CcSEcCtD
Olopatadine—Body temperature increased—Methotrexate—urinary bladder cancer	7.45e-05	0.000944	CcSEcCtD
Olopatadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	7.37e-05	0.000983	CbGpPWpGaD
Olopatadine—Dyspnoea—Doxorubicin—urinary bladder cancer	7.27e-05	0.000922	CcSEcCtD
Olopatadine—Feeling abnormal—Epirubicin—urinary bladder cancer	7.26e-05	0.000921	CcSEcCtD
Olopatadine—Somnolence—Doxorubicin—urinary bladder cancer	7.25e-05	0.000919	CcSEcCtD
Olopatadine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.21e-05	0.000914	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—CREBBP—urinary bladder cancer	7.16e-05	0.000956	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IFNA2—urinary bladder cancer	7.13e-05	0.000951	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.04e-05	0.000893	CcSEcCtD
Olopatadine—Fatigue—Doxorubicin—urinary bladder cancer	7.03e-05	0.000892	CcSEcCtD
Olopatadine—Pain—Doxorubicin—urinary bladder cancer	6.97e-05	0.000884	CcSEcCtD
Olopatadine—Body temperature increased—Epirubicin—urinary bladder cancer	6.97e-05	0.000884	CcSEcCtD
Olopatadine—Abdominal pain—Epirubicin—urinary bladder cancer	6.97e-05	0.000884	CcSEcCtD
Olopatadine—Hypersensitivity—Methotrexate—urinary bladder cancer	6.94e-05	0.00088	CcSEcCtD
Olopatadine—S100B—Innate Immune System—CREBBP—urinary bladder cancer	6.78e-05	0.000904	CbGpPWpGaD
Olopatadine—Asthenia—Methotrexate—urinary bladder cancer	6.76e-05	0.000857	CcSEcCtD
Olopatadine—S100A12—Immune System—S100B—urinary bladder cancer	6.74e-05	0.000899	CbGpPWpGaD
Olopatadine—S100B—Immune System—IFNA2—urinary bladder cancer	6.74e-05	0.000899	CbGpPWpGaD
Olopatadine—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.72e-05	0.000852	CcSEcCtD
Olopatadine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.67e-05	0.000846	CcSEcCtD
Olopatadine—Pruritus—Methotrexate—urinary bladder cancer	6.66e-05	0.000845	CcSEcCtD
Olopatadine—Hypersensitivity—Epirubicin—urinary bladder cancer	6.49e-05	0.000824	CcSEcCtD
Olopatadine—Abdominal pain—Doxorubicin—urinary bladder cancer	6.45e-05	0.000818	CcSEcCtD
Olopatadine—Body temperature increased—Doxorubicin—urinary bladder cancer	6.45e-05	0.000818	CcSEcCtD
Olopatadine—Diarrhoea—Methotrexate—urinary bladder cancer	6.44e-05	0.000817	CcSEcCtD
Olopatadine—Asthenia—Epirubicin—urinary bladder cancer	6.32e-05	0.000802	CcSEcCtD
Olopatadine—Pruritus—Epirubicin—urinary bladder cancer	6.24e-05	0.000791	CcSEcCtD
Olopatadine—Dizziness—Methotrexate—urinary bladder cancer	6.23e-05	0.00079	CcSEcCtD
Olopatadine—Diarrhoea—Epirubicin—urinary bladder cancer	6.03e-05	0.000765	CcSEcCtD
Olopatadine—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.01e-05	0.000762	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—ERBB2—urinary bladder cancer	6e-05	0.0008	CbGpPWpGaD
Olopatadine—Vomiting—Methotrexate—urinary bladder cancer	5.99e-05	0.000759	CcSEcCtD
Olopatadine—Rash—Methotrexate—urinary bladder cancer	5.94e-05	0.000753	CcSEcCtD
Olopatadine—Dermatitis—Methotrexate—urinary bladder cancer	5.93e-05	0.000752	CcSEcCtD
Olopatadine—Headache—Methotrexate—urinary bladder cancer	5.9e-05	0.000748	CcSEcCtD
Olopatadine—Asthenia—Doxorubicin—urinary bladder cancer	5.85e-05	0.000742	CcSEcCtD
Olopatadine—Dizziness—Epirubicin—urinary bladder cancer	5.83e-05	0.000739	CcSEcCtD
Olopatadine—Pruritus—Doxorubicin—urinary bladder cancer	5.77e-05	0.000732	CcSEcCtD
Olopatadine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	5.69e-05	0.000759	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—RBX1—urinary bladder cancer	5.69e-05	0.000758	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—ERBB2—urinary bladder cancer	5.67e-05	0.000757	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	5.61e-05	0.000749	CbGpPWpGaD
Olopatadine—Vomiting—Epirubicin—urinary bladder cancer	5.6e-05	0.000711	CcSEcCtD
Olopatadine—Nausea—Methotrexate—urinary bladder cancer	5.59e-05	0.000709	CcSEcCtD
Olopatadine—Diarrhoea—Doxorubicin—urinary bladder cancer	5.58e-05	0.000708	CcSEcCtD
Olopatadine—Rash—Epirubicin—urinary bladder cancer	5.56e-05	0.000705	CcSEcCtD
Olopatadine—Dermatitis—Epirubicin—urinary bladder cancer	5.55e-05	0.000704	CcSEcCtD
Olopatadine—Headache—Epirubicin—urinary bladder cancer	5.52e-05	0.0007	CcSEcCtD
Olopatadine—Dizziness—Doxorubicin—urinary bladder cancer	5.39e-05	0.000684	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—TSC1—urinary bladder cancer	5.35e-05	0.000713	CbGpPWpGaD
Olopatadine—Nausea—Epirubicin—urinary bladder cancer	5.24e-05	0.000664	CcSEcCtD
Olopatadine—Vomiting—Doxorubicin—urinary bladder cancer	5.19e-05	0.000658	CcSEcCtD
Olopatadine—Rash—Doxorubicin—urinary bladder cancer	5.14e-05	0.000652	CcSEcCtD
Olopatadine—Dermatitis—Doxorubicin—urinary bladder cancer	5.14e-05	0.000651	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—CDKN1A—urinary bladder cancer	5.13e-05	0.000684	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PTEN—urinary bladder cancer	5.12e-05	0.000682	CbGpPWpGaD
Olopatadine—Headache—Doxorubicin—urinary bladder cancer	5.11e-05	0.000648	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—JAG1—urinary bladder cancer	5.09e-05	0.000679	CbGpPWpGaD
Olopatadine—S100A12—Immune System—FGFR3—urinary bladder cancer	4.9e-05	0.000654	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—EP300—urinary bladder cancer	4.88e-05	0.000651	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—CDKN1A—urinary bladder cancer	4.85e-05	0.000647	CbGpPWpGaD
Olopatadine—Nausea—Doxorubicin—urinary bladder cancer	4.84e-05	0.000614	CcSEcCtD
Olopatadine—S100B—Innate Immune System—PTEN—urinary bladder cancer	4.84e-05	0.000645	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—SRC—urinary bladder cancer	4.74e-05	0.000633	CbGpPWpGaD
Olopatadine—S100B—Immune System—FGFR3—urinary bladder cancer	4.64e-05	0.000618	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—EP300—urinary bladder cancer	4.61e-05	0.000615	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	4.55e-05	0.000607	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—SRC—urinary bladder cancer	4.49e-05	0.000598	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	4.41e-05	0.000589	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CREBBP—urinary bladder cancer	4.17e-05	0.000557	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—EGFR—urinary bladder cancer	4.16e-05	0.000555	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CDH1—urinary bladder cancer	4.14e-05	0.000552	CbGpPWpGaD
Olopatadine—S100B—Immune System—CREBBP—urinary bladder cancer	3.95e-05	0.000526	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—EGFR—urinary bladder cancer	3.93e-05	0.000525	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—KRAS—urinary bladder cancer	3.93e-05	0.000524	CbGpPWpGaD
Olopatadine—S100B—Immune System—CDH1—urinary bladder cancer	3.92e-05	0.000522	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—KRAS—urinary bladder cancer	3.72e-05	0.000496	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NCOR1—urinary bladder cancer	3.71e-05	0.000494	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ERBB2—urinary bladder cancer	3.49e-05	0.000466	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—HRAS—urinary bladder cancer	3.34e-05	0.000445	CbGpPWpGaD
Olopatadine—S100B—Immune System—ERBB2—urinary bladder cancer	3.3e-05	0.000441	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TERT—urinary bladder cancer	3.27e-05	0.000436	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL2—urinary bladder cancer	3.17e-05	0.000422	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—HRAS—urinary bladder cancer	3.16e-05	0.000421	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.06e-05	0.000408	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.02e-05	0.000402	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—FGFR3—urinary bladder cancer	3e-05	0.0004	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL2—urinary bladder cancer	3e-05	0.000399	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CDKN1A—urinary bladder cancer	2.99e-05	0.000398	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PTEN—urinary bladder cancer	2.98e-05	0.000397	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ESR1—urinary bladder cancer	2.91e-05	0.000388	CbGpPWpGaD
Olopatadine—S100A12—Immune System—EP300—urinary bladder cancer	2.84e-05	0.000379	CbGpPWpGaD
Olopatadine—S100B—Immune System—CDKN1A—urinary bladder cancer	2.82e-05	0.000377	CbGpPWpGaD
Olopatadine—S100B—Immune System—PTEN—urinary bladder cancer	2.82e-05	0.000376	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.81e-05	0.000375	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.77e-05	0.00037	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HDAC4—urinary bladder cancer	2.77e-05	0.000369	CbGpPWpGaD
Olopatadine—S100A12—Immune System—SRC—urinary bladder cancer	2.76e-05	0.000369	CbGpPWpGaD
Olopatadine—S100B—Immune System—EP300—urinary bladder cancer	2.69e-05	0.000358	CbGpPWpGaD
Olopatadine—S100B—Immune System—SRC—urinary bladder cancer	2.61e-05	0.000349	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CREBBP—urinary bladder cancer	2.55e-05	0.00034	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IGF1—urinary bladder cancer	2.52e-05	0.000336	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	2.45e-05	0.000327	CbGpPWpGaD
Olopatadine—S100A12—Immune System—EGFR—urinary bladder cancer	2.42e-05	0.000323	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	2.42e-05	0.000323	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GLI1—urinary bladder cancer	2.32e-05	0.000309	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—RHOA—urinary bladder cancer	2.31e-05	0.000308	CbGpPWpGaD
Olopatadine—S100B—Immune System—EGFR—urinary bladder cancer	2.29e-05	0.000306	CbGpPWpGaD
Olopatadine—S100A12—Immune System—KRAS—urinary bladder cancer	2.29e-05	0.000305	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	2.29e-05	0.000305	CbGpPWpGaD
Olopatadine—S100B—Immune System—KRAS—urinary bladder cancer	2.16e-05	0.000289	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ERBB2—urinary bladder cancer	2.14e-05	0.000285	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CXCL8—urinary bladder cancer	2.03e-05	0.00027	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HRAS—urinary bladder cancer	1.95e-05	0.000259	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	1.94e-05	0.000259	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL2—urinary bladder cancer	1.94e-05	0.000258	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCND1—urinary bladder cancer	1.89e-05	0.000252	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.87e-05	0.00025	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CXCL8—urinary bladder cancer	1.87e-05	0.000249	CbGpPWpGaD
Olopatadine—S100B—Immune System—HRAS—urinary bladder cancer	1.84e-05	0.000245	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MMP9—urinary bladder cancer	1.83e-05	0.000244	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.83e-05	0.000244	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTEN—urinary bladder cancer	1.82e-05	0.000243	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.78e-05	0.000237	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.78e-05	0.000237	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EP300—urinary bladder cancer	1.74e-05	0.000232	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SRC—urinary bladder cancer	1.69e-05	0.000225	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.62e-05	0.000217	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—RBX1—urinary bladder cancer	1.59e-05	0.000212	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MYC—urinary bladder cancer	1.51e-05	0.000202	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TSC1—urinary bladder cancer	1.49e-05	0.000199	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EGFR—urinary bladder cancer	1.48e-05	0.000198	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.46e-05	0.000195	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—JAG1—urinary bladder cancer	1.42e-05	0.00019	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KRAS—urinary bladder cancer	1.4e-05	0.000187	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.38e-05	0.000184	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.35e-05	0.00018	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TP53—urinary bladder cancer	1.24e-05	0.000166	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.2e-05	0.00016	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HRAS—urinary bladder cancer	1.19e-05	0.000159	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—S100B—urinary bladder cancer	1.15e-05	0.000154	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—RHOA—urinary bladder cancer	1.09e-05	0.000146	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.08e-05	0.000144	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.05e-05	0.000141	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	1.03e-05	0.000138	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	1.01e-05	0.000134	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	9.73e-06	0.00013	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	9.58e-06	0.000128	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	9.15e-06	0.000122	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TERT—urinary bladder cancer	9.12e-06	0.000122	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	8.4e-06	0.000112	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	8.37e-06	0.000112	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	8.13e-06	0.000108	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	7.78e-06	0.000104	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	7.78e-06	0.000104	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	7.55e-06	0.000101	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	7.13e-06	9.5e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	7.04e-06	9.39e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	7e-06	9.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	6.61e-06	8.82e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	6.45e-06	8.6e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.27e-06	8.37e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	5.97e-06	7.96e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	5.66e-06	7.55e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	5.62e-06	7.5e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	5.41e-06	7.21e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	5.27e-06	7.03e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.23e-06	6.98e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	5.12e-06	6.83e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.1e-06	6.8e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	5.09e-06	6.79e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.86e-06	6.49e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	4.85e-06	6.47e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.81e-06	6.41e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.81e-06	6.41e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	4.72e-06	6.29e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.6e-06	6.14e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.52e-06	6.03e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.25e-06	5.67e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	4.23e-06	5.64e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	4.14e-06	5.52e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	3.91e-06	5.21e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	3.47e-06	4.63e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.45e-06	4.6e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	3.32e-06	4.43e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.31e-06	4.41e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.71e-06	3.62e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.36e-06	3.15e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.25e-06	3.01e-05	CbGpPWpGaD
